CLINICAL STUDY

TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing’s syndrome and related to bone turnover

Tove Lekva1,2,4, Thor Ueland2,4, Hege Bøyum1,3, Johan Arild Evang1,2,4, Kristin Godang1 and Jens Bollerslev1,4

1Section of Specialized Endocrinology, Department of Endocrinology, 2Research Institute for Internal Medicine, 3Division of Obstetrics and Gynaecology, National Resource Centre for Women’s Health and 4Faculty of Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway

(Correspondence should be addressed to T Lekva who is now at Section of Specialized Endocrinology and Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, University of Oslo, PO Box 4950 Nydalen, 0424 Oslo, Norway; Email: tove.lekva@medisin.uio.no)

Abstract

Objective: Patients with endogenous Cushing’s Syndrome (CS), as long-time treated patients with exogenous glucocorticoids (GCs), have severe systemic manifestations including secondary osteoporosis and low-energy fractures. The aim of the present study was to investigate the functional role of TXNIP in bone with focus on osteoblast (OB) differentiation and OB-mediated osteoclast activity and function in vitro.

Design and methods: Nine bone biopsies from CS before and after surgical treatment were screened for expressionals candidate genes. Microarray analyses revealed that the gene encoding TXNIP ranked among the most upregulated genes. Subsequent in vitro and in vivo studies were performed.

Results: We found that TXNIP gene in bone is downregulated in CS following surgical treatment. Furthermore, our in vivo data indicate novel associations between thiorexin and TXNIP. Our in vitro studies showed that silencing TXNIP in OBs was followed by increased differentiation and expression and secretion of osteocalcin as well as enhanced activity of alkaline phosphatase. Moreover, treating osteoclasts with silenced TXNIP OB media showed an increased osteoclast activity.

Conclusions: TXNIP expression in bone is highly regulated during the treatment of active CS, and by GC in bone cells in vitro. Our data indicate that TXNIP may mediate some of the detrimental effects of GC on OB function as well as modulate OB-mediated osteoclastogenesis by regulating the OPG/RANKL ratio.

European Journal of Endocrinology 166 1039–1048

Introduction

Glucocorticoids (GCs) are widely used as antiinflammatory and immunosuppressive agents to control different acute and chronic diseases. Hypercortisolism is a well-known cause of bone loss, and patients with endogenous Cushing’s syndrome (CS) frequently display low bone mass and fragility fractures. Cortisol excess inhibits bone formation, increases bone resorption, impairs calcium absorption from the gut, and affects the secretion of several hormones, cytokines, and growth factors with potential influence on bone metabolism (1). Sustained and prolonged hypercortisolism leads to a rapid early phase of bone mineral density (BMD) decline due to higher bone resorption, which is followed later by a slower and more progressive phase of impaired bone formation (2). The initial effect of GC at the cellular level is stimulation of osteoblastic (OB) cells to increase the production of RANKL and reduce the production of OPG (2), thereby turning the RANKL/OPG ratio in favor of osteoclastogenesis (3, 4). Moreover, GC directly reduces the number and function of OB, the latter as the most detrimental effect of GC on bone metabolism (2). At the bone resorptive site, GC acts directly on osteoclasts and prolongs their life span and thereby the resorative capacity (2).

Thiorexin 1 (TRX) regulates the redox state of cells and is induced and secreted in response to oxidative stress and inflammation. Elevation of serum/plasma TRX levels has been reported in patients with diabetes mellitus, impaired glucose tolerance, arterial hypertension, hypercholesterolemia, atherosclerosis (5, 6, 7), and various types of malignancies (8). Several studies suggest that TRX activity can be modulated by the interaction with thiorexin interacting protein-1 (TXNIP, also called VDUP-1 for vitamin D3-upregulated protein or TBP-2 for TRX-binding protein-2) (9, 10). TXNIP is a multifunctional protein and a major messenger of intracellular physiological processes and upregulated by various types of stress (9). Its expression has been shown to be induced by dexamethasone (Dex) and may mediate GC-induced apoptosis (11).

In order to search for regulated genes in target tissues of potential pathogenetic importance, we used global gene expression profiling of bone biopsies from CS patients, before and 3 months after surgical treatment,
to screen for changes in gene expression. We found the gene encoding TXNIP as one of the most regulated genes in relation to treatment. Based on the well-known effects of GC excess on bone tissue, we investigated whether TXNIP could modulate OB differentiation and osteocalcin (OC) synthesis in OB. Moreover, we investigated the effects of OB signaling on osteoclast activity and function in vitro.

Materials and methods

Subjects

Nine patients diagnosed with CS (12) were recruited based on clinical evaluation and biochemical workup (13, 14). Biological specimens (blood, bone biopsies) were first collected at baseline (untreated), and then again 3 ± 1.3 (mean ± S.D.) months after surgical treatment. Twenty-three new CS patients were recruited in the period 2002–2009 (blood samples before and after treatment from 16 patients, 0.9 ± 0.9 (mean ± S.D.) years after surgical treatments). Seventeen and eight of the female patients were pre- and postmenopausal respectively. Twenty-three patients were diagnosed with Cushing’s disease (two of them removed adrenal cortex adenoma at a later time), eight with adrenal cortex adenoma, and one with an ectopic ACTH-producing adenoma. CS patients received tapering doses of cortisone in the postoperative phase. A group of 29 healthy subjects matched by age, sex, and body mass index were used as controls. Blood samples were drawn fasting in the morning. All patients and controls gave signed informed consent, and the study was approved by the Regional Committee of Medical and Health Research Ethics (REK) in Eastern Norway and conducted according to the Declaration of Helsinki II.

Bone biopsies

Transiliac crest bone biopsies with an inner diameter of 6 mm were obtained from CS patients under local anesthesia and stored in liquid nitrogen until analysis (15). Alternative hips were used for the two biopsies. All microarray raw data have been deposited on Gene Expression Omnibus (GEO) under accession number GSE30159.

Biochemical markers

Circulating OC was measured by EIA, provided by Quidel (Santa Clara, CA, USA) and N-terminal telopeptides of type-1 collagen (NTX), TRX by ELISA, Redox Bioscience, Inc. (Osaka, Japan), and cortisol was measured as previously reported (12). Cortisol measurement also detects cortisone acetate.

BMD measurement

BMD was measured by dual-energy X-ray absorptiometry (LUNAR Corp., Madison, WI, USA) (13). The values were expressed as Z-scores.

RNA isolation from bone biopsies and cultured cells

Extraction of total RNA was performed using Trizol (Invitrogen) as previously described (12). RNA was purified using Qiagen RNeasy micro kit (Qiagen). The integrity was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and concentrations determined by optical density (OD) readings on Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).

Microarray

Microarray analysis was performed as previously described (12), using biotin-labeled cRNA probes hybridized to HG U133 Plus 2.0 Arrays (Affymetrix, Inc., Santa Clara, CA, USA).

Real-time RT-PCR

RT was performed using a High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA). Quantification of mRNA was performed using standard curve method of the ABI Prism 7500 (Applied Biosystems). For real-time RT-PCR, sequence-specific oligonucleotide primers were designed using Primer Express Software version 2.0 (Applied Biosystems; Table 1).

Cell culture

The human fetal OB (hFOB) cell line 1.19 was obtained from American Type Culture Collection (CRL-11372, Rockville, MD, USA) (16, 17). hFOB cells proliferate and exhibit early OB characteristics at 33.5 °C (the permissive temperature, where the temperature-sensitive mutant SV 40 large T antigen is active), but have the ability to acquire mature OB features when grown at 39.5 °C (the restrictive temperature, when the SV 40 large T antigen is inactive).

Cellular differentiation and Dex treatment

Cells were grown at 33.5 °C until 90% confluence before shifting the temperature to 39.5 °C to induce differentiation for 2 days or more, as indicated. For time–course and dose–response experiments hFOB cells were seeded in triplicate cultures (24-well plates; 3.0 × 10^4 cells/well) and differentiated at 39.5 °C for 2 days, followed by treatment with Dex (10^{-8} and 10^{-6} M) or vehicle (0.6% ethanol), as indicated.
Alkaline phosphatase staining

Alkaline phosphatase (ALP) staining was determined using Sigma kit 104-LS, as previously described (Sigma)(18).

Silencing of TXNIP gene expression in hFOB

A pool of four siRNA duplexes specific for human TXNIP (silencing RNA TXNIP (siTXNIP)) and scramble control pool (silencing RNA scramble control (siSCR)) were designed by Dharmacon (Lafayette, CO, USA). The sense strand sequences were TXNIP1, 5'-GAAUA-CAUGUUCCGGAUAUUU-3'; TXNIP2, 5'-GCAAACAGACUUCGGAGUAUU-3'; TXNIP3, 5'-GCAAACAGACUUCGGAGUAUU-3'; TXNIP4, 5'-GCAAACAGACUUCGGAGUAUU-3'. hFOB cells were grown in 12-well plates (5×10^4 cells/well) for 24 h at 33.5 °C (40% confluent) in antibiotic-free medium containing 10% FCS. For transfection, 50 nM siRNA duplexes and 6 μl HiPerFect transfection reagent (Qiagen) were prepared in OptiMem with glutamax-1 (Gibco–Invitrogen) at a final volume of 300 μl in 12-well plates (Costar.). After 4 h, 300 μl differentiation media recommended from the manufacturer were added to the cells for the remaining period of 2 and 7 days, changing the media after 4 days.

Silencing of TXNIP in normal human OBs

The normal human OBs (NHOst) cell line was obtained from Lonza (Walkersville, Inc., Walkersville, MD, USA) and silenced for 2 days with siTXNIP and siSCR. For transfection, 50 nM siRNA duplexes and 6 μl HiPerFect transfection reagent (Qiagen) were prepared in OptiMem with glutamax-1 (Gibco–Invitrogen) at a final volume of 300 μl in 12-well plates (Costar.). After 4 h, 300 μl differentiation media recommended from the manufacturer were added to the cells for the remaining period of 2 and 7 days, changing the media after 4 days.

OC secretion from hFOB

OC measurement from supernatant of siTXNIP and siSCR hFOB and NHOst was performed using the Human Gla-Osteocalcin High Sensitive EIA kit provided by Takara (Shiga, Japan).

Lactate dehydrogenase cytotoxicity assay

A lactate dehydrogenase (LDH) cytotoxicity assay kit (Roche) was used for quantification of plasma membrane damage in hFOB differentiated for 2 days followed by treatment with Dex (10^{-6} M) or vehicle (0.6% ethanol) for 24 h. One hundred microliters of supernatant were transferred into corresponding wells of a clear 96-well plate and followed by addition of 100 μl of the reaction mixture to each well and incubation for 30 min in the dark. The absorbance at 490 nm was measured using a microplate reader to analyze the release of LDH into the media.

Western blot

Cells were washed twice in PBS, scraped in lysis buffer, and stored at −20 °C until use. Eighty micrograms of total protein of each extract were incubated at 97 °C for 2 min before being separated on any kDs SDS–PAGE gels (Bio-Rad Laboratories) and transferred onto polyvinylidene-dene difluoride membranes (SEN: Life Science, Boston, MA, USA). Membranes were incubated with mouse anti-human TXNIP (MBL International, Woburn, MA, USA) antibody over night at 4 °C and for 1 h at room temperature. The membrane was washed with the TBS-T for 5 min and then treated with secondary antibody ( Sigma) for 1 h.

Table 1 Primer sequences used in PCR reactions.

<table>
<thead>
<tr>
<th>Genes</th>
<th>GenBank</th>
<th>Forward (5′–3′)</th>
<th>Reverse (5′–3′)</th>
<th>Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALP</td>
<td>NM_000478</td>
<td>GGAAGAGCTTCAAAACCAGGA</td>
<td>TGCGTCGAAGAGACCAATA</td>
<td>109</td>
</tr>
<tr>
<td>RUNX2</td>
<td>NM_001024630</td>
<td>CGGATGCGCTCTGCTGTTAT</td>
<td>GGTCTCACTTTGCTGTC</td>
<td>89</td>
</tr>
<tr>
<td>OC</td>
<td>NM_001917</td>
<td>CCTCACACTCTCGCCCTATT</td>
<td>GGACACAAAGGCTGCACCTT</td>
<td>105</td>
</tr>
<tr>
<td>COL1A2</td>
<td>NM_000089</td>
<td>ATGCCTGGCCAGCCAGTTGA</td>
<td>TCGCATGGTACTGGTGCCTGA</td>
<td>119</td>
</tr>
<tr>
<td>β-Actin</td>
<td>NM_001101</td>
<td>AGGCACCATGGGCTGAT</td>
<td>TCTCCAGGCTTGAGGAGGT</td>
<td>127</td>
</tr>
<tr>
<td>RANKL</td>
<td>NM_033012</td>
<td>GTGCAAAAGGAAATTACACATATCGT</td>
<td>AACATGAGCCTACATACCAT</td>
<td>76</td>
</tr>
<tr>
<td>OPG</td>
<td>NM_002546</td>
<td>ATCAATCCAATGATGGAATAGATGT</td>
<td>CGGTAAATCTTGGAGAAGCAGCA</td>
<td>80</td>
</tr>
<tr>
<td>TXNIP</td>
<td>NM_006472.3</td>
<td>GAAGCTCCTCTCCCTGCTATAGGA</td>
<td>CCACTGTCATCTCGACAGAGAGGGTGT</td>
<td>81</td>
</tr>
<tr>
<td>Caspase 3</td>
<td>NM_004346</td>
<td>TGATTATCTGGACTAGGGT</td>
<td>CAGACCCAGAGATGTGTTCAAC</td>
<td>80</td>
</tr>
<tr>
<td>Caspase 8</td>
<td>NM_001228</td>
<td>AGTGGGCAAGAGAATTAGCATT</td>
<td>TCTCAATATCCCAGGTGTTCAAG</td>
<td>138</td>
</tr>
<tr>
<td>BCL2</td>
<td>NM_000633</td>
<td>CGGTGTTGGAGGAGGCTT</td>
<td>TGACGCTTCCACACACATGGA</td>
<td>93</td>
</tr>
<tr>
<td>BAX</td>
<td>NM_004324</td>
<td>CCGCCGTGGACACAGACT</td>
<td>CGGCCCAAGGAGGTGAATTT</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>NM_138761.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NM_138763</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NM_138764</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
temperature with anti-mouse IgG (Cell Signaling Technology, Denver, MA, USA) HRP-conjugated secondary antibody. HRP signals were developed using the ECL Plus western blotting detection system (GE Healthcare Bio-Sciences, Uppsala, Sweden) and visualized by Luminiscent Image Analyzer 4000 mini (Fujifilm, Tokyo, Japan). To ensure equal loading of protein the blots were stripped and reprobed with antibody against β-actin (Sigma–Aldrich).

**Differentiation and Dex treatment of osteoclasts**

Human osteoclast precursor cells (Lonza Walkersville, Inc.) were cultured for 8 days. At day 5, the cells were treated with different doses of Dex (10⁻¹¹ to 10⁻⁸ M) or vehicle (0.1% ethanol) for 48 h.

**Silencing of TXNIP in osteoclasts**

Human osteoclast precursors were grown in quadruplicate cultures in 12-well plates for 6 days. The same siRNA duplexes specific for human TXNIP were used as in the hFOB experiment. For transfection, 50 nM siRNA duplexes and 6 μl HiPerFect transfection reagent (Qiagen) were prepared in OptiMem with glutamax-1 (Gibco–Invitrogen) at a final volume of 300 μl. After 4 h, 300 μl medium were added to the cells for the remaining period of 2 days, including cells treated with vehicle (0.1% ethanol) and Dex (10⁻⁶ M) for 24 h.

**Osteoclasts stimulated with silenced TXNIP OB medium**

Human osteoclast precursors were grown in quadruplicate cultures in 12-well plates for 6 days before they were cultured 50/50 with normal growth medium and media from hFOB (siTXNIP and siSCR treated with and without Dex (10⁻⁶ M) or vehicle, for 24 h in the silencing experiment) for 2 days.

**Tartrate-resistance acid phosphatase activity in osteoclasts media**

Conditioned media and freshly prepared reaction buffer were added to a 96-well plate as previously described (12). The reaction was left in the dark 1 h at 37 °C and stopped with 100 μl of 0.3 M NaOH and OD was measured at 405 nm.

**Osteoclasts from CD14 + monocytes**

CD14 + monocytes were selected using MACS cell sorting system (Miltenyi Biotech, Surrey, UK). Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous blood obtained from healthy female donors, and diluted twofold in saline. PBMCs were obtained by centrifugation through Ficoll; 30 ml of diluted blood were layered onto 10 ml of lymphoprep solution (Nycomed, Birmingham, UK) in a sterile 50 ml tube (Falcon, BD Biosciences, San Jose, CA, USA). Blood was then subjected to centrifugation at 350 g for 25 min. Cells at the interface were removed and washed twice in RPMI (Gibco–Invitrogen Corp.) and counted and seeded into 24-well plates, 3 × 10⁵ cells/well.

Osteoclasts were differentiated and maintained in α-minimal essential medium (Gibco, Invitrogen Corp.) with 10% fetal bovine serum (FBS), l-glutamine (2 mM), penicillin/streptomycin (50 U/ml and 50 μg/ml) in a humidified atmosphere (37 °C, 5% CO₂) containing macrophage colony-stimulating factor (M-CSF) and RANKL (25 ng/ml; R&D, Minneapolis, MN, USA) changing media every 4–5 days. On day 16, osteoclasts were treated with siTXNIP and siSCR or siTXNIP and siSCR OB media from the hFOB silencing experiment for 2 days in α-minimal essential medium with 0.6% Ultrasor.

**Osteoassay human bone plate**

CD14 + monocytes were seeded onto osteoassay human bone plate (Lonza Walkersville, Inc.), 5 × 10⁴ cells/well. Osteoclasts were differentiated and maintained in α-minimal essential medium (Gibco, Invitrogen Corp.) with 10% FBS, l-glutamine (2 mM), penicillin/streptomycin (50 U/ml and 50 μg/ml) in a humidified atmosphere (37 °C, 5% CO₂) containing M-CSF and RANKL (25 ng/ml; R&D) changing media every 4–5 days. On day 16, osteoclasts were treated with condition media from siTXNIP and siSCR OB and resorption media from the calcifiuor kit (Lonza Walkersville, Inc.) with 0.1% FCS, (50/50) for 5 days on osteoassay plates. Calcium release using the Calcifiuor assay kit was measured by fluorescence, directly proportional to the calcium content.

**Statistical analysis**

Unless stated otherwise, all values are expressed as mean ± S.E.M. Wilcoxon ranked sum test was used to evaluate differences between the sample of interest and its own control in bone biopsies and serum samples. For analysis of time–course and dose–response, one-way ANOVA was used. Unpaired Student’s sample t-test (two-tailed) was used to evaluate differences between control and treated cells and siTXNIP and scramble control–treated cells. Between controls and CS samples nonparametric Mann–Whitney was used. Relationships between variables were tested by Spearman’s correlation (R). Average signal levels on the microarrays for all differentially regulated mRNAs included were at least 50, with a P value < 0.05 (paired t-test). A P value of < 0.05 was considered significant. All in vitro
studies were performed three times with representative experiments presented.

Results

In vivo

Patient's characteristics are given in Table 2. Patients with CS were characterized and compared with age, body mass index, and sex-matched healthy controls. Cortisol levels were increased compared with controls and decreased following surgery, reaching levels that were lower than the controls. BMD in CS patients were significantly lower compared with controls for all compartments investigated (Z-scores).

TXNIP mRNA decreases markedly in bone biopsies following treatment

To screen for differentially expressed genes locally in bone tissue from CS patients, total RNA from iliac crest bone biopsies was subjected to whole-genome gene expression profiling. Of 975 significantly regulated mRNAs, TXNIP was one of the most upregulated genes in untreated vs treated CS patients (P < 0.001). Quantitative real-time RT-PCR validated the microarray results showing a median 1.7-fold decrease following successful surgery (P = 0.028; Fig. 1A).

Circulating TRX and biochemical bone markers in CS patients

TXNIP is considered a negative regulator of TRX function and/or expression (10). We therefore analyzed serum levels of TRX in CS patients (Fig. 1B) and found significantly increased levels of TRX (median fold 1.4, P = 0.001) compared with controls. Following surgical cure an additional increase was observed. A trend toward decreased serum OC was observed in CS at baseline followed by a substantial increase reaching levels markedly higher than controls after treatment (Fig. 1C). As for bone resorption, NTX was increased at baseline compared with controls and increased further following treatment (Fig. 1D).

Correlations between TXNIP, TRX and markers of bone metabolism

Before treatment, the relative gene expression of TXNIP was positively correlated to circulating TRX levels (R = 0.75, n = 7, P = 0.05). Moreover, the change in TXNIP gene expression and the change in circulating TRX levels following surgical treatment tended to be correlated (R = 0.71, n = 7, P = 0.07). We found no correlations between changes in TXNIP gene expression in bone biopsies or changes in circulating levels of TRX to serum levels of OC or NTX (data not shown).

Table 2 Baseline characteristics of the study population. Data are given as mean ± s.d. BMD values are given as Z-scores.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Controls (n = 29)</th>
<th>Cushing pre-surgery (n = 32)</th>
<th>Cushing post-surgery (n = 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>45 ± 11</td>
<td>41 ± 11</td>
<td>44 ± 10</td>
</tr>
<tr>
<td>Women/men (n)</td>
<td>19/10</td>
<td>25/7</td>
<td>13/3</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.6 ± 4.4</td>
<td>30.3 ± 7.0</td>
<td>31.2 ± 7.5</td>
</tr>
<tr>
<td>Cortisol (nmol/l)</td>
<td>417 ± 214.3</td>
<td>634 ± 214.6ab</td>
<td>163 ± 174.2ab</td>
</tr>
<tr>
<td>Female pre/postmenopausal</td>
<td>ND</td>
<td>17/8</td>
<td>ND</td>
</tr>
<tr>
<td>BMD Total</td>
<td>0.53 ± 1.1</td>
<td>-0.89 ± 1.3⁴</td>
<td>ND</td>
</tr>
<tr>
<td>Lumbar spine</td>
<td>0.12 ± 1.4</td>
<td>-1.77 ± 1.5³</td>
<td>ND</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>0.20 ± 0.9</td>
<td>-1.62 ± 1.3³</td>
<td>ND</td>
</tr>
<tr>
<td>Radius ultradistal</td>
<td>0.40 ± 1.3</td>
<td>-1.67 ± 1.5³</td>
<td>ND</td>
</tr>
</tbody>
</table>

⁴Indicates significant levels between controls and CS.
⁵Between CS pre- and post-surgery.

Correlations between TXNIP, TRX and markers of bone metabolism

Before treatment, the relative gene expression of TXNIP was positively correlated to circulating TRX levels (R = 0.75, n = 7, P = 0.05). Moreover, the change in TXNIP gene expression and the change in circulating TRX levels following surgical treatment tended to be correlated (R = 0.71, n = 7, P = 0.07). We found no correlations between changes in TXNIP gene expression in bone biopsies or changes in circulating levels of TRX to serum levels of OC or NTX (data not shown).

Figure 1 TXNIP gene in bone and serum measures of TRX, OC, and NTX. (A) Expression of TXNIP mRNA in bone biopsies from nine CS patients before and 3 months after surgery. Data are normalized to ß-actin (Wilcoxon ranked sum test). Serum levels of (B) TRX (C) OC, and (D) NTX in 32 CS at pre-surgical levels, 16 CS at 0.9 ± 0.9 (mean ± s.e.d.) years after surgical treatment and 29 age-, sex-, and BMI-matched controls (nonparametric Mann–Whitney between controls and CS and Wilcoxon ranked sum test between pre- and post-surgery samples).

www.eje-online.org
Figure 2 Increased TXNIP expression after Dex treatment and increased OC and ALP expression and protein in siTXNIP hFOB. (A) hFOB were expanded at 33.5 °C until ~90% confluent and induced to differentiate by raising the temperature to 39.5 °C. At the indicated time points, expression of TXNIP mRNA was assessed by real-time RT-PCR. The data were normalized to β-actin mRNA and expressed as relative levels. P values represent one-way ANOVA. (B) Cells grown to subconfluence at 33.5 °C were induced to differentiate at 39.5 °C for 2 days before they were treated with either vehicle (ethanol) or Dex at concentration of 10^{-6} and 10^{-8} M for 6 and 24 h. Relative mRNA levels for TXNIP were determined by real-time RT-PCR. Data are normalized to β-actin mRNA and expressed as relative levels. P values represent one-way ANOVA. (C) Silencing of TXNIP in hFOB differentiated to OB. Gene expression following silencing, 24 h at 33.5 °C and 2, 5, and 7 days at 39.5 °C, using 25 nM siTXNIP (black columns) and 25 nM scrambled siRNA as negative control (white columns). (D) Western blot of TXNIP in total lysates from the same cultured cells. mRNAs for (D) TXNIP and (E) OC, (F) secretion of OC at 2, 5, and 7 days of cultured cells, (G) mRNAs for BALP, and (I) RUNX2. All mRNAs were normalized to β-actin and expressed as relative levels. (H) In parallel cultures, the cells were characterized for ALP activity by histochemical staining after 5 days. (J) NHOst were silenced for 2 days, using 25 nM siTXNIP (black columns) and 25 nM scrambled siRNA as negative control (white columns), followed by differentiating for 2 and 7 days, measuring mRNAs for TXNIP and OC. (K) Secretion of OC at 7 days of differentiated NHOst. Results are presented as mean ± S.E.M.; *P<0.05, **P<0.01, and ***P<0.001 indicate difference between siSCR- and siTXNIP-treated cells (unpaired Student’s sample t-test).
**In vitro**

**TXNIP is upregulated during hFOB differentiation and by Dex** We next examined if TXNIP was regulated during differentiation or by Dex in human OB *in vitro*. Expression of TXNIP mRNA was assessed by real-time PCR and exhibited upregulated expression in maturing hFOB at 39.5 °C (i.e. differentiating conditions, Fig. 2A). In hFOB cells differentiated for 2 days at 39.5 °C and treated with two doses of Dex (10^{-8} and 10^{-6} M) for 6 h and 24 h respectively, TXNIP mRNA levels increased in a dose-dependent manner (*P*<0.05, Fig. 2B).

**Silencing of TXNIP increases OB markers in hFOB and NHOst** The role of TXNIP in OB development and differentiation was further assessed by silencing TXNIP mRNA expression in hFOB cells using a pool of four siRNA and scramble siRNA as a negative control. TXNIP mRNA expression was reduced by more than 50% in hFOB treated with TXNIP siRNA (siTXNIP) vs scrambled siRNA controls (siSCR) for 2 days of differentiation (Fig. 2C) and a similar and more sustained (i.e. differences also at 5 and 7 days) result was seen at protein level (Fig. 2D), resulting in significantly increased levels of typical OB-related mRNAs such as OC (Fig. 2E) and ALP (Fig. 2G) and further by ALP staining (Fig. 2H), while runt-related transcription factor 2 (RUNX2) mRNA was not affected (Fig. 2I). When investigating effects of TXNIP silencing on secreted OC, we found an increased OC secretion in the media of siTXNIP cells compared with controls (Fig. 2F). A second model of TXNIP knockdown in NHOst was used and ~30% reduced TXNIP expression was obtained. Despite the low silencing result, we found a significant increase in OC expression and secretion from the siTXNIP NHOst after 2 and 7 days of differentiation respectively (Fig. 2J and K).

**Effects of TXNIP on apoptosis in hFOB** To assess the extent of plasma membrane damage, the release of the cytoplasmic enzyme LDH was quantified after 2 days of differentiation followed by 10^{-6} M Dex treatment for 24 h (Fig. 3A). We found no increase of LDH release from hFOB cells treated with Dex, or between siTXNIP compared with siSCR-treated cells. In addition, the mRNAs of the BCL2/BAX ratio were not different in Dex treated or between siTXNIP- and siSCR-treated cells (Fig. 3B), but an increased expression of caspase 3 in Dex-treated cells compared with vehicle was demonstrated, and the mRNAs for caspase 3 and 8 were suppressed in siTXNIP compared with siSCR Dex-treated cells (Fig. 3C and D).

**Effects of TXNIP on OB-mediated osteoclastogenesis and direct effects in osteoclasts** To explore if TXNIP expression in OB could affect OB-mediated osteoclastogenesis, we first investigated effects on OPG and RANKL (TNFSF11) expression in OB. Silencing of TXNIP in hFOB increased RANKL and decreased OPG mRNA expression compared with scramble controls, leading to an increased RANKL/OPG ratio in siTXNIP-treated cells during basal conditions (Fig. 4A), thus favoring osteoclastogenesis.

To further explore TXNIP effects on OB-mediated osteoclastogenesis, human osteoclast precursor cells were treated with siTXNIP- and siSCR-conditioned media from the hFOB silencing experiment. An upregulation of tartrate-resistant acid phosphatase (TRAP) activity was detected when treating the cells with siTXNIP OB media (Fig. 4B). To explore TXNIP function on bone resorption in a bone resorption model, we used human bone plates coated with osteoclasts differentiated from CD14+ cells. Using an siTXNIP OB medium, an increased calcium release from the bone was detected, indicating higher resorption activity with the siTXNIP OB medium (Fig. 4C). Differentiation of human osteoclast precursors showed no regulation of TXNIP expression (Fig. 3D). However, treating the cells with different doses of Dex showed an increased TXNIP expression (Fig. 3E). To explore direct effects on TXNIP in osteoclasts, we silenced TXNIP and found no difference of TRAP activity in the condition media in siTXNIP-treated osteoclasts compared with siSCR-treated osteoclasts (Fig. 4F). All osteoclast experiments were validated in osteoclasts differentiated from CD14+ monocytes (data not shown). The main findings of the present study are summarized in Fig. 5.
Discussion

In the present study, we show that TXNIP expression in bone biopsies from CS patients is highly downregulated following surgical treatment. Circulating levels of TRX were increased in the patients at baseline and increased further in relation to treatment. Furthermore, we show that TXNIP is upregulated during OB differentiation in vitro and by Dex stimulation of OB in a dose-dependent manner. Finally, our study indicates that TXNIP may regulate osteoclastogenesis through OB signaling. These data suggest that TXNIP is highly upregulated by GC in bone tissue and that TXNIP by itself is of importance for bone metabolism.

We performed global gene expression profiling of bone biopsies from CS patients before and after treatment and found that the gene TXNIP is highly expressed and significantly downregulated following successful surgery. These clinical translational findings are in accordance with previous studies showing TXNIP to be induced by GC in a murine T-cell lymphoma cell line (11). However, bone biopsies consist of different cell types (e.g. OB, osteoclasts, osteocytes, and mesenchymal stem cells) and our data reflect the overall tissue levels of transcripts, and not their precise cellular source. TXNIP gene expression at baseline was associated with increased circulating level of TRX also at baseline and following treatment, substantiating the close relation between the two proteins (9, 10). In accordance with the decrease in TXNIP in bone biopsies following surgical cure and normalization of cortisol levels, we found TXNIP to be upregulated in a dose-dependent manner by Dex in human OB and osteoclasts in vitro. Moreover, TXNIP was also upregulated during OB differentiation. Furthermore, silencing of TXNIP gene expression in OB showed a sustained increase in levels of typical OB markers (e.g. OC and bone specific alkaline phosphatase (BALP)). These findings, indicating a considerable attenuating effect of TXNIP on OB differentiation and function, are in agreement with the bone formative phenotype observed in active CS,
characterized by decreased OB number and function with low levels of biochemical markers of bone formation (3), as well as the rapid increase in bone turnover with increased bone formation, following normalization of cortisol levels. GCs promote the apoptosis of OB and osteocytes in vitro via the activation of caspases (1, 19). We found no evidence of decreased apoptosis in silenced TXNIP hFOB, but an increased expression after Dex treatment in caspase 3 and a suppressed expression after silencing TXNIP of caspase 3 and 8 were observed, and supports the possible suppressive effects of TXNIP on OB. GC also represses transcription of OC through a GC response element (20), and thereby making the interpretation of GC effects on OC changes in CS complicated. We found OC to be upregulated by silencing TXNIP, without Dex in the experiment, thus suggesting TXNIP to be directly involved in OC suppression. In this study, the cellular effects were searched on the hFOB cell line. From the review of Liu et al. (21), some important issues about different OB models in vitro have been addressed. The most widely used OB model systems in vitro are primary cultures derived from normal human and rodent bone fragments, or osteosarcoma cell lines generated from human bone tumors. Each of these cell sources has strengths and limitations. In effort to overcome these limitations, Harris et al. (16) established a conditionally immortalized, human–fetal–OB cell line, hFOB 1.19 that was stably transfected with a gene coding for a temperature-sensitive mutant of the SV40 large T antigen. Resultant hFOB cells express OB-specific phenotypic markers and mineralize extracellular matrix. Later, Subramaniam et al. (22) characterized hFOB 1.19 as an immortalized, but nontransformed, cell line with minimal chromosome abnormalities and normal spectrum of matrix proteins. They reported that the hFOB cells appeared to be an excellent model system for the study of OB biology in vitro. In a previous study (12) we assessed transcripts characteristicly expressed by OB; i.e. ALP, OC, and COL1A2, and the bone-remodeling cytokines OPG and RANKL in relation to differentiation and Dex treatment. We demonstrated satisfying results for a normal OB phenotype. Another important advantage of this cell line is property that the cells are fast differentiated into mature OB, compared with normal OB, which need ~ 3 weeks for full differentiation. The hFOB are also easy to transfect and therefore an excellent model to study mechanisms with RNA interference. Another limitation in the present study is the lack of bone biopsies from a control group for comparing TXNIP expression in bone in vivo. However, although we cannot establish if the TXNIP in bone is increased in active CS, the strong correlation between TXNIP and TRX, as well as the marked increase in TRAP levels compared with control at baseline, may suggest so.

The OPG/RANKL system is of major importance for the coordinated coupling principle in bone remodeling (4, 23). We found that silencing of TXNIP in hFOB decreased OPG and increased RANKL, indicating that decreased OB expression of TXNIP favors bone resorption. Indeed, when mature osteoclasts were cultured with conditioned media from siTXNIP OB, an increase in TRAP activity and calcium release from bone in a bone resorption model was observed. Although these data, indicating a limiting effect of increased TXNIP on OB-mediated bone resorption, may seem in contrast with the slightly enhanced bone resorption observed in CS patients, they possibly indicate that in the presence of excess cortisol the effect of TXNIP on bone resorption is limited, and that direct effects of GC on osteoclasts dominate. However, following surgical cure, a marked increase in bone turnover, with increased bone formation and resorption, is observed. Thus, the decline in TXNIP following surgery and normalization of cortisol levels, leading to enhanced osteoblastogenesis, may favor bone resorption through an increased RANKL/OPG ratio, and thereby explaining our previous observation of a restoration of coupling of bone remodeling following the treatment of CS (14). Together, these observations imply that TXNIP may be a major regulator of OB-mediated osteoclastogenesis.

In conclusion, the present translational study showed that TXNIP expression is highly upregulated in bone tissue during treatment of active CS, and by GC in bone cells in vitro. Moreover, our data indicate that TXNIP may mediate some of the detrimental effects of GC on OB function as well as modulate OB-mediated osteoclastogenesis by regulating the OPG/RANKL ratio, possibly playing a role in the pathogenesis of human glucocorticoid-induced osteoporosis.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements

The authors are grateful to Dr Ole Kristoffer Olstad and the Affymetrix Microarray Core Facility at Oslo University Hospital/Ullevål for performing and analyzing the microarray experiment.

References


Received 19 December 2011
Revised version received 21 March 2012
Accepted 26 March 2012